Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer Clinical research trials and Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer. Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "C" Clinical Trials Conditions > Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer



Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

For Condition: adenocarcinoma of the prostate,stage 2 prostate cancer,stage 3 prostate cancer
Status: Recruiting
Sponsor(s): Oregon Health and Science University , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy followed by surgery in treating patients who have localizedprostate cancer.
Details: OBJECTIVES: - Determine the 5-year freedom from prostate-specific antigen (PSA) recurrence in patients treated with this regimen. - Define the maximum tolerated dose of neoadjuvant docetaxel and mitoxantrone followed by prostatectomy in patients with high-risk localized prostate cancer. (Phase I completed as of 2/15/02) - Determine the toxicity of this regimen in these patients. - Determine the PSA response rate and pathologic response rate in patients treated with this regimen. - Determine the clinical response in patients treated with this regimen. - Determine the overall survival of patients treated with this regimen. - Determine the surgical margin status at time of prostatectomy in patients treated with this regimen. OUTLINE: This is a dose-escalation study of mitoxantrone. (Phase I completed as of 2/15/02) Patients receive neoadjuvant docetaxel and mitoxantrone weekly on weeks 1-3. Treatment repeats once a week for a total of 4 courses. Patients receive escalating doses of mitoxantrone until the maximum tolerated dose is determined. (Phase I completed as of 2/15/02) Patients undergo prostatectomy 2-4 weeks after completion of neoadjuvant chemotherapy. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - High-risk, as defined by 1 of the following: - Stage T2b (palpable bilateral involvement) or surgically resectable T3 - PSA 15 ng/mL or greater - Gleason grade greater than 4+3 (4+3, 4+4, or 5+any, but not 3+4) - At least a 50% chance of prostate cancer recurrence within 5 years - Planned prostatectomy as primary therapy - No evidence of bone metastases by bone scan - No evidence of lymph nodes greater than 2 cm on pelvic CT scan (scan required only if PSA greater than 40 ng/mL) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 10 years Hematopoietic: - WBC at least 3,000/mm^3 - Neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Conjugated bilirubin no greater than upper limit of normal (ULN) - Alkaline phosphatase no greater than 4 times ULN - ALT no greater than 2 times ULN (1.5 times ULN if alkaline phosphatase greater than 2.5 times ULN) Renal: - Not specified Cardiovascular: - Ejection fraction greater than 50% by MUGA Other: - No other malignancy within the past 5 years except nonmelanoma skin cancer - No significant active medical illness that would preclude study therapy - No peripheral neuropathy grade 2 or greater - No hypersensitivity to drugs formulated with polysorbate-80 - No significant contraindications to corticosteroids PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior cytotoxic chemotherapy - No other concurrent cytotoxic chemotherapy Endocrine therapy: - No prior or concurrent conventional hormonal therapy Radiotherapy: - No prior or concurrent radiotherapy (external beam or brachytherapy) Surgery: - See Disease Characteristics Other: - No prior or concurrent cryotherapy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
TomaszBeer,  Study Chair,  Oregon Health and Science University

Cancer Institute at Oregon Health and Science University *Recruiting*
Portland,  Oregon,  97201-3098
United States
Recruiting Oregon  Center Clinical Trials Hotline 503-494-1080


Additional Information:
Study ID Numbers:  CDR0000068719;  OHSU-HOR-00037-L,OHSU-6082,NCI-G01-1962
Study Start Date: 
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00017563

Other Stage 3 Prostate Cancer Studies:
1. Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

2. Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

3. NCI HIGH PRIORITY CLINICAL TRIAL --- Prostatectomy Compared With Watchful Waiting in Treating Patients With Stage I or Stage II Prostate Cancer

4. Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

5. BMS-247550 With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

Related Studies:

Other stage 3 prostate cancer Clinical Trials
Other Oregon Clinical Trials
Other Portland Clinical Trials

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Modify your Search

  Other stage 3 prostate cancer Clinical Trials
  Other Oregon Clinical Trials
  Other Portland Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103